Align Technology (ALGN)
(Delayed Data from NSDQ)
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 6:18 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 6:18 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Brookdale (BKD) Concludes Transactions to Extend Debt Repayment
by Zacks Equity Research
Brookdale (BKD) completes two financing transactions to push its debt maturities until September 2025, thereby relieving it from the debt repayment burden for next year and focusing on core operations.
Align Technology (ALGN) Up 30% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Align Technology (ALGN)
by Shaun Pruitt
Undoubtedly, investors are hoping that the end-of-the-year rally can continue for the broader stock market but the recent spike in Align Technology (ALGN) shares appears to be overdone.
Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod
by Zacks Equity Research
Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.
Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger
by Zacks Equity Research
Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.
Align Technologies (ALGN) Secures Updated Medical Device License
by Zacks Equity Research
Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.
Align Technology (ALGN) Moves 11.1% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Bear of the Day: Becton, Dickenson and Co (BDX)
by David Bartosiak
Earnings have been retreating on this Bear of the Day.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
Align Technology (ALGN) Up 14% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
CNMD or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.
Compared to Estimates, Align Technology (ALGN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Align Technology (ALGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Align Technology (ALGN) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of -5.31% and 3.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.
Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align (ALGN) Gains From New Launches, Strategic Partnerships
by Zacks Equity Research
Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Cencora (COR) to Your Portfolio Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
STERIS' (STE) Improved Volume, New Buyouts Drive Growth
by Zacks Equity Research
On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.